Radiation-induced amphiregulin drives tumour metastasis
- PMID: 40369065
- DOI: 10.1038/s41586-025-08994-0
Radiation-induced amphiregulin drives tumour metastasis
Erratum in
-
Publisher Correction: Radiation-induced amphiregulin drives tumour metastasis.Nature. 2025 Nov 10. doi: 10.1038/s41586-025-09862-7. Online ahead of print. Nature. 2025. PMID: 41214352 No abstract available.
Abstract
The anti-tumour effect of radiotherapy beyond the treatment field-the abscopal effect-has garnered much interest1. However, the potentially deleterious effect of radiation in promoting metastasis is less well studied. Here we show that radiotherapy induces the expression of the EGFR ligand amphiregulin in tumour cells, which reprogrammes EGFR-expressing myeloid cells toward an immunosuppressive phenotype and reduces phagocytosis. This stimulates distant metastasis growth in human patients and in pre-clinical mouse tumour models. The inhibition of these tumour-promoting factors induced by radiotherapy may represent a novel therapeutic strategy to improve patient outcomes.
© 2025. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: R.R.W. has stock and other ownership interests with Boost Therapeutics, Immvira, Reflexion Pharmaceuticals, Coordination Pharmaceuticals, Magi Therapeutics and Oncosenescence. He has served in a consulting or advisory role for Aettis, Astrazeneca, Coordination Pharmaceuticals, Genus, Merck Serono S.A., Nano proteagen, NKMax America and Shuttle Pharmaceuticals. He has a patent pending entitled ‘Methods and Kits for Diagnosis and Triage of Patients with Colorectal Liver Metastases’ (PCT/US2019/028071). He has received research grant funding from Varian and Regeneron. He has received compensation including travel, accommodations, or expense reimbursement from Astrazeneca, Boehringer Ingelheim and Merck Serono S.A. C.H. has stock and other ownership interests with Accent Therapeutics and Aferna Green. C.H. is a scientific advisory board member of Aferna Green and Rona Therapeutics. A. Piffkó has consulted for Related Sciences/Danger Bio and owns equity in Danger Bio. E.L. receives research funding to study the biology of ovarian cancer from AbbVie through The University of Chicago that is unrelated to this work. A patent application has been submitted by A. Piffkó, H.L.L., S.P.P. and R.R.W and is pending at the date of publication. The other authors declare no competing interests.
References
-
- Lomax, M. E., Folkes, L. K. & O’Neill, P. Biological consequences of radiation-induced DNA damage: relevance to radiotherapy. Clin. Oncol. 25, 578–585 (2013). - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
